As a result, we found that the administration of recombinant Tpp53 (rTpp53) on the skin could ameliorate IMQ-induced psoriasis, as revealed by the improvement of pathological lesions of psoriasis (epidermis hyperplasia and parakeratosis, acanthosis, epidermal extension, and inflammatory infiltration), and the inhibited expression of IL-23/IL-17 axis related cytokines and chemokines in psoriasis skins. The gene discussed is IL23A; the disease is psoriasis.